DAVID A. NATHAN, M.D., F.A.C.P.; MARVIN L. MEITUS, M.D.; LEWIS CAPLAND, M.D.; MAURICE LEV, M.D.
Various undesirable effects have been reported following the use of phenylbutazone (Butazolidin) in the therapy of arthritis and allied rheumatic disorders. Since the initial American clinical evaluation by Kuzell, Schaffarzick, Brown and Mankle,1 the medical literature is gradually acquiring more and more case histories of heretofore undescribed reactions as well as previously experienced characteristic toxic manifestations due to this compound. First synthesized by the chemists of J. R. Geigy, S. A., of Basle, Switzerland, phenylbutazone (3, 5-dioxo-1, 2-diphenyl-4 n-butyl pyrazolidin sodium) is a synthetic derivative of pyrazol. Aminopyrine (Pyramidon) has the chemical formula 1-phenyl-2, 3-dimethyl-4-dimethylamino-5 pyrazolone, thus indicating a definite
DAVID A. NATHAN, MARVIN L. MEITUS, LEWIS CAPLAND, MAURICE LEV. DEATH FOLLOWING PHENYLBUTAZONE (BUTAZOLIDIN) THERAPY: REPORT OF A CASE(DEATH FOLLOWING PHENYLBUTAZONE (BUTAZOLIDIN) THERAPY: REPORT OF A CASE*). Ann Intern Med. 1953;39:1096–1103. doi: 10.7326/0003-4819-39-5-1096
Download citation file:
Published: Ann Intern Med. 1953;39(5):1096-1103.
Results provided by:
Copyright © 2017 American College of Physicians. All Rights Reserved.
Print ISSN: 0003-4819 | Online ISSN: 1539-3704
Conditions of Use